Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Upfront Autologous Hematopoietic Stem Cell Transplantation Versus Immunosuppressive Medication in Early Diffuse Cutaneous Systemic Sclerosis: an International Multicentre, Open-label, Randomized Con-trolled Trial

NCT04464434 is registered in ClinicalTrials.gov with UMC Utrecht as lead sponsor.

NCT NCT04464434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04464434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Upfront Autologous Hematopoietic Stem Cell Transplantation Versus Immunosuppressive Medication in Early Diffuse Cutaneous Systemic Sclerosis: an International Multicentre, Open-label, Randomized Con-trolled Trial
Lead sponsor
UMC Utrecht
Phase
Phase 4
Overall status
Completed
Start date
September 17, 2020
Completion date
March 19, 2026
Enrollment
60 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

autologous stem cell transplantation, cyclophosphamide, mycophenolate mofetil, scleroderma, scleroderma, diffuse, systemic scleroses, diffuse, systemic sclerosis, treatment strategy